Journal: Cancer genomics & proteomics

Article Title: Association of BIM Deletion Polymorphism and BIM-? RNA Expression in NSCLC with EGFR Mutation.

PMID/MRN: 27807070

Publication Date: 2016-11-04

Abstract:

This pilot study assessed the association of BIM deletion polymorphism and BIM RNA isoform in patients with EGFR-positive non-small cell lung cancer (NSCLC). The study included 33 patients with EGFR-positive NSCLC treated with gefitinib. BIM deletion polymorphism and BIM RNA isoform (EL/L/S/?) were determined by polymerase chain reaction (PCR). BIM-? expression was significantly higher in patients with BIM deletion polymorphism than among those without BIM deletion polymorphism inside tumors (p=0.038) and around tumors (p=0.0024). Relative BIM-? expression was significantly higher in patients with BIM deletion polymorphism than among those without BIM deletion polymorphism (p=0.0017). Patients with BIM-? had significantly shorter progression-free survival than those without BIM-? (median: 304 vs. 732 days; p=0.023). Expression of BIM-? mRNA and BIM deletion polymorphism were strongly associated. BIM-? overexpression may have a role in apoptosis related to EGFR-tyrosine kinase inhibitor. Copyright© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.